Spinocerebellar ataxia type 23 (SCA23) is an inherited neurodegenerative disorder belonging to the group of spinocerebellar ataxias, characterized by progressive damage to the nervous system, especially the cerebellum and spinal cord. The main manifestations of the disease include ataxic movement disorders, gait instability, dysmetria, and impaired coordination and balance. In addition to ataxic manifestations, patients may experience other neurological symptoms such as lateral myoclonus, acute cerebrovascular accidents, and possible cognitive impairment. SCA23 is caused by mutations in the TTC2 gene, which leads to disturbances in the functionality of neurons and, as a result, to a deterioration in their ability to adequately transmit signals. These changes require a multidisciplinary approach to diagnosis, treatment, and rehabilitation of patients.
History of the disease and interesting historical facts
Spinocerebellar ataxia type 23 was first described in the early 21st century when a series of genetic studies identified a specific mutation in the TTC2 gene responsible for the disorder. Studies conducted in 2006 and 2008 demonstrated that SCA23 is caused by dominant mutations that are inherited. Interestingly, the discovery of this ataxia occurred within the framework of broader genetic studies devoted to various variants of spinocerebellar ataxia, the total number of which currently exceeds 40. The discovery of SCA23 has become a significant contribution to the understanding of the pathogenesis of ataxias, which in turn has opened up new opportunities for the development of diagnostic tests and therapeutic strategies.
Epidemiology
The prevalence of spinocerebellar ataxia type 23 varies by region and ethnic group, with the highest incidence rates reported among certain populations, such as indigenous peoples in northern parts of Europe. A general estimate from preventive studies suggests that SCA23 affects approximately 1 in 5,000 to 10,000 people in these regions. However, some families are at increased risk of developing the disorder, highlighting the importance of genetic counseling and early detection of the mutation in family members.
Genetic predisposition to this disease
Spinocerebellar ataxia type 23 is caused by a mutation in the TTC2 gene located on chromosome 16. This mutation results in duplication of the gene transcript, which alters the function of the encoded protein, which in turn causes a cascade of neurodegenerative changes. Research shows that the presence of one abnormal allele of the gene allows susceptible individuals to develop the disease. The level of TTC2 gene expression and its correlation with clinical symptoms have also attracted the attention of scientists investigating possible molecular mechanisms of the disease.
Risk factors for the development of this disease
Risk factors for developing SCA23 are primarily related to genetic predisposition, as the disease is inherited in a dominant manner. There are other potential factors that influence the manifestation of the disease, including:
- Age: The risk of developing age-related symptoms increases with the patient's age.
- Family history: Having affected relatives significantly increases the likelihood of developing SCA23.
- Environmental factors, although their role is not as clearly defined.
It should be emphasized that, unlike other forms of ataxia, external factors such as chemical exposure or trauma have not been established as direct causes of SCA23.
Diagnosis of this disease
Diagnosis of spinocerebellar ataxia type 23 is based on a comprehensive approach that includes clinical, laboratory and radiological methods. The main symptoms of SCA23 may include:
- Ataxic movements
- Dysmetria
- Impaired coordination
- Muscle weakness
Laboratory tests may include genetic testing to identify mutations in the TTC2 gene. Radiological tests, such as MRI, may show evidence of atrophy of the cerebellum and other CNS structures. Differential diagnosis includes ruling out other forms of ataxia and neurological diseases such as amyotrophic lateral sclerosis and other neurodegenerative disorders.
Treatment
There is currently no specific disease for spinocerebellar ataxia type 23. Treatment is mainly symptomatic and includes:
- Pharmacological treatment: aimed at reducing symptoms such as muscle spasms and discomfort.
- Physiotherapy: helps with rehabilitation and improving coordination.
- Surgical interventions: in rare cases used to correct atrophy.
Some studies have focused on the possibility of using neuroprotective drugs and new approaches aimed at slowing the progression of the disease.
List of medications used to treat this disease
The drugs used include:
- Diazedapam – to reduce muscle spasms and manage anxiety.
- Selective serotonin reuptake inhibitors – for the treatment of depression.
- Levodopa – sometimes used to manage movement disorders.
However, it must be emphasized that treatment should always be selected individually depending on the nature of the manifestations of the disease.
Disease monitoring
SCA23 follow-up should include regular neurological monitoring to assess symptom progression and possible complications. The prognosis for this disease is highly individual, as the progression can be either slow or rapid. Complications may include complete loss of independence and the development of comorbidities such as depression or anorexia, which requires comprehensive rehabilitation and support.
Age-related features of the disease
Spinocerebellar ataxia type 23 can present at any age, with onset most often occurring in middle age, around 30-50 years. In children, the manifestations of SCA23 may be less pronounced and in many cases remain unrecognized until adolescence or young adulthood. In older people, the disease may progress more rapidly, which is associated with age-related changes in the body.
Questions and Answers
- How is SCA23 inherited? — Spino-cerebellar ataxia type 23 is inherited in a dominant manner, meaning that only one parent can pass on the mutated allele to cause the disease in a child.
- What are the main symptoms of the disease? — The main symptoms of SCA23 include ataxia, impaired motor coordination, dysmetria and muscle weakness.
- Are there any specific treatments? — No, there is no specific treatment for SCA23. Treatment is symptomatic and aimed at alleviating the patient’s condition.
- What is the role of genetic testing? — Genetic testing allows us to confirm the diagnosis and assess the risk for family members if there are sick relatives.
- What is the outlook for a patient with SCA23? — The prognosis for patients with SCA23 varies; some trials show long-term stabilisation, but progression can be rapid in others.
